Live
Endpoints NewsAcceleron leaders and Westlake jumpstart new IPF biotechBioWorldDaewoong nabs Innovo’s preclinical IBD asset in ₩663B dealBioWorldLife sciences ‘sweet’ opportunity in US-China talksBioWorldMedical devices evolving into intelligent, adaptive systemsBioWorldWHO declares Ebola outbreak a public health emergency of international concernBioWorldBiopharma deal and M&A values soar in early 2026BioPharma DiveBioMarin drug acquired in buyout misses goal in rare disease studyEndpoints NewsThe state of consumer healthEndpoints NewsQ&A: Novo research chief Petersen says streamlined R&D speeds discoveryEndpoints NewsWave aims for monthly dosing with RNA editing treatment for AATDBioPharma DiveA migraine drugmaker heads to the public markets through reverse mergerFierceBiotechFacing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
BioWorld Feb 11, 2026

Kunshan Xinyunda Biotechnology synthesizes new ADCs

Kunshan Xinyunda Biotechnology synthesizes new ADCs

Original
Body unavailable. Use the original source.